The role of neuroplasticity in dopaminergic therapy for Parkinson disease

Keyphrases

• Parkinson's Disease 100%
• Dopamine 100%
• Neuroplasticity 100%
• Dopaminergic Therapy 100%
• Long-duration Response 100%
• Basal Ganglia 66%
• Short-term Response 66%
• Dopamine Replacement Therapy 66%
• Corticostriatal Plasticity 66%
• Novel Therapeutics 33%
• Psychiatric Disorders 33%
• Response to Therapy 33%
• Motor Function 33%
• Motor Symptoms 33%
• Pharmacotherapy 33%
• Therapeutic Strategies 33%
• Dopamine Level 33%
• Neurological Disorders 33%
• Disease-modifying Effect 33%
• Experience-dependent 33%
• Motor Response 33%
• Disease Modification 33%
• Aberrant Plasticity 33%

Neuroscience

• Dopaminergic 100%
• Parkinson's Disease 100%
• Neuroplasticity 100%
• Basal Ganglia 66%
• Epileptic Absence 33%
• Neurological Disorder 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Dopamine Receptor Stimulating Agent 100%
• Parkinson's Disease 100%
• Disease 66%
• Symptom 33%
• Epileptic Absence 33%
• Replacement Therapy 33%
• Neurologic Disease 33%
• Pharmacotherapy 33%